SAN FRANCISCO — Cytokinetics CEO Robert Blum is very clear. The company — on track to secure U.S. approval in September for a drug to treat a serious heart condition — is not for sale.
Cytokinetics, Inc. is a biopharmaceutical company ... The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered ...
Hosted on MSN1mon
Why Cytokinetics Stock Was a Nearly 5% Winner TodayThat morning, Cytokinetics announced that Sanofi has acquired the Greater China development and commercialization rights to aficamten from Chinese healthcare company Corxel. This is a drug ...
With U.S. stock markets set to open in two hours, Sportradar Group AG Cl A (SRAD) was up 6.9% in pre-market trading, and Cytokinetics Inc. (CYTK) was up 6.1%. Back To Top ...
Shares of NASDAQ CYTK opened at $48.87 on Friday. Cytokinetics has a fifty-two week low of $36.24 and a fifty-two week high of $110.25. The company has a market cap of $5.77 billion, a PE ratio of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback